Compare IMUX & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | KRMD |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 192.5M |
| IPO Year | 2013 | 2019 |
| Metric | IMUX | KRMD |
|---|---|---|
| Price | $14.99 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $36.00 | $6.50 |
| AVG Volume (30 Days) | ★ 174.0K | 154.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | N/A | $20.32 |
| Revenue Next Year | N/A | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $0.51 | $3.20 |
| 52 Week High | $15.84 | $6.61 |
| Indicator | IMUX | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 50.10 |
| Support Level | $0.74 | $4.20 |
| Resistance Level | $15.81 | $4.30 |
| Average True Range (ATR) | 0.82 | 0.23 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 51.75 | 28.89 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.